Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-03-20
2007-03-20
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S454000, C514S456000, C514S443000, C514S451000, C549S263000, C549S273000, C549S433000, C549S434000, C549S032000, C549S031000, C562S465000, C562S463000
Reexamination Certificate
active
10479262
ABSTRACT:
Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1and W, R1is (CH2)n—CH(OR2)—(CH2)mE1, —(CH)═C(OR2)—(CH2)mE, —(CH2)n—CH(Y)—(CH2)mE or (CH)═C(Y)—(CH2)mE; wherein E is COOR3, C1–C3alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1–C6alkyl, haloalkyl and aryl-C0-4-alkyl; R2is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR4, —COOR4, —CONR5R6, —C(S)R4, —C(S)OR4or C(S)NR5R6, R3is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH2—, —CH2CH2— or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R1. R4–R6are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5387672 (1995-02-01), Bucci et al.
patent: 5462954 (1995-10-01), Baker et al.
patent: 6054453 (2000-04-01), Lohray et al.
patent: 6506757 (2003-01-01), Tajima et al.
patent: 6541474 (2003-04-01), Kikuchi et al.
patent: 2002/0032202 (2002-03-01), Kikuchi et al.
patent: 2003/0153579 (2003-08-01), Tajima et al.
patent: 2 385 081 (2001-04-01), None
patent: 0 903 343 (2003-05-01), None
patent: WO 9636347 (1996-11-01), None
patent: WO99/62870 (1999-12-01), None
patent: WO99/62872 (1999-12-01), None
patent: WO/0220482 (2002-03-01), None
Bucci et al., 1995, CAS : 122 :196942.
Haigh, D., et al., “Non-thiazolidinedione Antihyperglycaemic Agents. Part 3: The Effects of Stereochemistry on the Potency of α-Methoxy-β-phenylpropanoic Acids,”Bioorganic&Medicinal Chemistry, 7: 821-830 (1999).
Kersten, S., et al., “Roles of PPARs in Health and Disease,”Nature, 405: 421-424 (2000).
Ardecky Robert J.
Brooks Dawn Alisa
Crespo Rafael Ferritto
Finger Maria Martin-Ortega
Gonzales Garcia Maria Rosario
Eli Lilly and Company
Hamilton Brook Smith & Reynolds P.C.
Ligand Pharmaceuticals Inc.
McKane Joseph K.
Shiao Robert
LandOfFree
Modulators of peroxisome proliferator activated receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of peroxisome proliferator activated receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of peroxisome proliferator activated receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3726547